Sorafenib is a multi-kinase inhibitor approved for the treatment of renal cell and hepatocellular carcinoma. Adverse cutaneous reactions are a very common side effect of the medication. We report the development of hidradenitis suppurativa (HS) in a patient after initiation of treatment with sorafenib.
View Article and Find Full Text PDFOur patient initially blamed the lesions on the surgical tape used after her C-section; a skin biopsy told another story.
View Article and Find Full Text PDF